Cancer Research
S2104 Study
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
AGE: 18+ years old
GENDER: All
HEALTHY PARTICIPANTS: No
GENDER: All
HEALTHY PARTICIPANTS: No
CONDITION: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor (pNET)
TYPE: Interventional Study
LOCATION: UH Cleveland Medical Center
LOCATION: UH Cleveland Medical Center
Learn More About This Research Study
To learn more about this study, please call study coordinator, Debbie Donohue at 216-844-4784 or complete the online form below.
Study Purpose
The purpose of this study is to evaluate recurrence-free survival in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only.
Who Can Participate
Participants 18 years old and older diagnosed with diagnosed with pancreatic neuroendocrine carcinoma or have metastatic malignant neoplasm in the liver may be eligible for this study.